Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials-Reference-Cited by-同舟云学术

Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials

Published:2014-09 Issue:9 Volume:38 Page:1048-1054
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Huang Hejing,Zhou Lili,Peng Lihui,Fu Weijun,Zhang Chunyang,Hou Jian

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. Cancer statistics, 2010;Jemal;CA: a Cancer J Clin,2010

2. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008

3. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010;Brenner;Haematologica,2009

4. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG);Kastritis;Leukemia,2009

5. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma with secondary amyloidosis: Dysphagia as the first symptom: A case report;Medicine;2024-07-12

2. Patients with multiple myeloma or monoclonal gammopathy of undetermined significance—diagnosis, treatment, and follow-up;Deutsches Ärzteblatt international;2022-04-08

3. Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data;Frontiers in Pharmacology;2020-12-11

4. Multiple myeloma with primary amyloidosis presenting with digestive symptoms: A case report and literature review;Arab Journal of Gastroenterology;2020-03

5. High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group;Oncology Letters;2019-09-27